As the market absorbs news of some serious safety issues in a Phase III study of Ionis Pharmaceuticals Inc.'s familial amyloidosis drug inotersen, the company is stressing the drug's convenience advantages, including subcutaneous delivery with fewer injection reactions than the competing infused patisiran from Alnylam Pharmaceuticals Inc. and no need for high-dose steroids.
Designed with Ionis's antisense platform, inotersen (IONIS-TTRRx) is a once-weekly subcutaneously-delivered therapy that inhibits the production of transthyretin (TTR)